Roche’s $230m acquisition of Anadys Pharmaceuticals today highlights the Swiss group’s attempts to gain some ground in a race in which it surprisingly lags the competition. Having dominated the treatment landscape for hepatitis C for the last ten years with best-selling interferon and ribavirin standard of care products in Pegasys and Copegus, Roche has struggled to keep pace with the development of novel therapies which are set to revolutionise the field.The Anadys deal means Roche now has a pipeline of candidates from each of the three most encouraging new classes of hepatitis C drug (see table below). Yet the Swiss healthcare giant’s progress to this point has been disappointingly slow, hampered by some in-house research failures and partnering choices which so far appear to have backed the wrong horse. Further deals will be required if Roche is to make up for lost time.
This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions
Follow us on Twitter